News

Latest news

  • 02 August 2024
    FDA has accepted a BLA for bentracimab, the first and only ticagrelor reversal agent, for filing and priority review
    Pleasanton, CA and Philadelphia, PA – 2 August 2024: SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB), who acquired exclusive US rights to bentracimab from SFJ and will commercialize bentracimab in the United States, announced today that the US Food and Drug Administration (FDA) has accepted the bentracimab […]
    Read release
  • 31 July 2024
    SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million
    Philadelphia, PA, 31 July 2024: SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. (NYSE: EBS) for an up-front payment of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon first achievement of a milestone relating to […]
    Read release
  • 30 May 2024
    SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth
    SERB appoints Vanessa Wolfeler as its new Chief Executive Officer
    Read release

News archive

Date

Title

    You are leaving the SERB.com global corporate website
    This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
    Choose your region